Aim: To determine whether immunotherapy with HPV6 L1 virus-like particles (VLPs) without
adjuvant (VLP immunotherapy) reduces recurrence of genital warts following destructive …

Aim To determine whether immunotherapy with HPV6 L1 virus like particles (VLPs) without
adjuvant (VLP immunotherapy) reduces recurrence of genital warts following destructive …

A phase 1b randomised placebo controlled blinded dose ranging study of HPV6 L1 Virus-
Like Particles (VLPs) as therapy for genital warts. Men (201) and women (171) ages 18–65 …

Conclusion The increasing incidence of HPV infections is of mounting concern and the most
prevalent clinical manifestation of this communicable disease is genital warts. Although …

Introduction: Human papillomavirus (HPV) is one of the most common causes of sexually
transmitted diseases in men and women worldwide, especially in developing countries. The …

Background: The appearance of genital warts varies. Flat or resembling raspberries or
cauliflower, they can be found in a variety of shapes. They begin as little red or pink growths …

Wart therapies involve methods of targeted lesion destruction, as well as selective
immunologic modification. While there are several therapeutic options, no treatment has …

Anogenital warts are the most common clinical manifestation of human papillomavirus
(HPV) infections. Although easy to recognize, asymptomatic anogenital warts (condylomata …

Genital infection with human papillomavirus (HPV) is a common STI. Reliable estimates
indicate a lifetime risk of infection of more than 50% for the population. Genital HPV infection …

Genital wart is one of the most commonly found human mucosal viral infection caused by the
Human Papillomavirus (HPV). Genital warts can present as papules, plaques or blisters that …